Amplicon library for bidirectional (2×250 bp) sequencing on Illumina MiSeq platform was constructed using universal primers 515f, 5′-GTGCCAGCMGCCGCGGTAA-3′ and 806r, 5′-GGACTACHVGGGTWTCTAAT-3′ ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Leading American genomic sequencing firm Illumina is the first biotech company on Beijing’s list. More than 60 per cent of the world’s genetic sequencing data is generated by Illumina’s ...

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

(RTTNews) - Below are the earnings highlights for Illumina Inc. (ILMN): Earnings: $187 million in Q4 vs. -$176 million in the same period last year. EPS: $1.17 in Q4 vs. -$1.11 in the same period ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...